vs
PMV Pharmaceuticals, Inc.（PMVP）与Arcadia Biosciences, Inc.（RKDA）财务数据对比。点击上方公司名可切换其他公司
PMV Pharmaceuticals, Inc.的季度营收约是Arcadia Biosciences, Inc.的1.4倍（$1.2M vs $901.0K），Arcadia Biosciences, Inc.净利率更高（-148.3% vs -1464.0%，领先1315.8%），Arcadia Biosciences, Inc.同比增速更快（-25.8% vs -46.1%），过去两年Arcadia Biosciences, Inc.的营收复合增速更高（-4.5% vs -35.4%）
PMV Pharmaceuticals是一家临床阶段生物制药企业，专注于开发针对p53抑癌基因突变的精准肿瘤疗法，p53是人类癌症中最常见的突变基因之一。其在研管线主打产品用于治疗难治性实体瘤与血液恶性肿瘤，满足全球肿瘤患者未被满足的医疗需求。
阿卡迪亚生物科学是一家美国上市农业生物技术企业，总部位于加利福尼亚州戴维斯，专注于开发可提升作物品质与产量的作物性状改良技术，该公司部分股权归道德指南针公司所有。
PMVP vs RKDA — 直观对比
营收规模更大
PMVP
是对方的1.4倍
$901.0K
营收增速更快
RKDA
高出20.3%
-46.1%
净利率更高
RKDA
高出1315.8%
-1464.0%
两年增速更快
RKDA
近两年复合增速
-35.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.2M | $901.0K |
| 净利润 | $-18.0M | $-1.3M |
| 毛利率 | — | 21.4% |
| 营业利润率 | -1561.8% | -152.8% |
| 净利率 | -1464.0% | -148.3% |
| 营收同比 | -46.1% | -25.8% |
| 净利润同比 | 21.6% | 67.1% |
| 每股收益（稀释后） | $-0.33 | $-0.97 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PMVPRKDA
| Q4 25 | $1.2M | $901.0K | ||
| Q3 25 | $1.5M | $1.3M | ||
| Q2 25 | $1.7M | $1.5M | ||
| Q1 25 | $1.9M | $1.2M | ||
| Q4 24 | $2.3M | $1.2M | ||
| Q3 24 | $2.6M | $1.5M | ||
| Q2 24 | $2.8M | $1.3M | ||
| Q1 24 | $3.0M | $987.0K |
净利润PMVPRKDA
| Q4 25 | $-18.0M | $-1.3M | ||
| Q3 25 | $-21.1M | $856.0K | ||
| Q2 25 | $-21.2M | $-4.5M | ||
| Q1 25 | $-17.4M | $2.6M | ||
| Q4 24 | $-23.0M | $-4.1M | ||
| Q3 24 | $-19.2M | $-1.6M | ||
| Q2 24 | $-1.2M | $1.1M | ||
| Q1 24 | $-15.3M | $-2.4M |
毛利率PMVPRKDA
| Q4 25 | — | 21.4% | ||
| Q3 25 | — | 32.1% | ||
| Q2 25 | — | 43.4% | ||
| Q1 25 | — | 43.2% | ||
| Q4 24 | — | 31.9% | ||
| Q3 24 | — | 32.9% | ||
| Q2 24 | — | 51.5% | ||
| Q1 24 | — | 52.3% |
营业利润率PMVPRKDA
| Q4 25 | -1561.8% | -152.8% | ||
| Q3 25 | -1521.8% | -88.5% | ||
| Q2 25 | -1353.8% | -34.4% | ||
| Q1 25 | -1114.4% | 44.2% | ||
| Q4 24 | -1100.5% | -187.7% | ||
| Q3 24 | -837.0% | -114.5% | ||
| Q2 24 | -720.1% | — | ||
| Q1 24 | -617.2% | -160.9% |
净利率PMVPRKDA
| Q4 25 | -1464.0% | -148.3% | ||
| Q3 25 | -1422.9% | 65.7% | ||
| Q2 25 | -1255.0% | -306.4% | ||
| Q1 25 | -901.1% | 216.6% | ||
| Q4 24 | -1005.7% | -334.5% | ||
| Q3 24 | -735.2% | -104.9% | ||
| Q2 24 | -43.3% | 81.2% | ||
| Q1 24 | -517.3% | -245.5% |
每股收益（稀释后）PMVPRKDA
| Q4 25 | $-0.33 | $-0.97 | ||
| Q3 25 | $-0.40 | $0.62 | ||
| Q2 25 | $-0.41 | $-3.26 | ||
| Q1 25 | $-0.34 | $1.90 | ||
| Q4 24 | $-0.45 | $-2.99 | ||
| Q3 24 | $-0.37 | $-1.18 | ||
| Q2 24 | $-0.02 | $0.78 | ||
| Q1 24 | $-0.30 | $-1.78 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $112.9M | $4.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $104.7M | $4.1M |
| 总资产 | $116.6M | $6.5M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资PMVPRKDA
| Q4 25 | $112.9M | $4.6M | ||
| Q3 25 | $129.3M | $5.9M | ||
| Q2 25 | $142.3M | $4.4M | ||
| Q1 25 | $160.4M | $3.2M | ||
| Q4 24 | $169.5M | $4.2M | ||
| Q3 24 | $182.8M | $6.6M | ||
| Q2 24 | $212.9M | $8.1M | ||
| Q1 24 | $197.9M | $8.5M |
股东权益PMVPRKDA
| Q4 25 | $104.7M | $4.1M | ||
| Q3 25 | $121.0M | $5.4M | ||
| Q2 25 | $140.6M | $4.5M | ||
| Q1 25 | $160.1M | $8.9M | ||
| Q4 24 | $176.1M | $6.2M | ||
| Q3 24 | $197.9M | $10.3M | ||
| Q2 24 | $214.3M | $11.7M | ||
| Q1 24 | $212.7M | $10.6M |
总资产PMVPRKDA
| Q4 25 | $116.6M | $6.5M | ||
| Q3 25 | $133.8M | $8.6M | ||
| Q2 25 | $152.9M | $7.8M | ||
| Q1 25 | $170.6M | $13.0M | ||
| Q4 24 | $191.3M | $13.5M | ||
| Q3 24 | $223.5M | $15.2M | ||
| Q2 24 | $237.5M | $17.4M | ||
| Q1 24 | $236.9M | $16.0M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-17.2M | $-861.0K |
| 自由现金流经营现金流 - 资本支出 | $-17.2M | — |
| 自由现金流率自由现金流/营收 | -1396.4% | — |
| 资本支出强度资本支出/营收 | 1.2% | 0.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-73.6M | — |
8季度趋势，按日历期对齐
经营现金流PMVPRKDA
| Q4 25 | $-17.2M | $-861.0K | ||
| Q3 25 | $-19.8M | $-257.0K | ||
| Q2 25 | $-18.3M | $-2.0M | ||
| Q1 25 | $-18.3M | $-1.6M | ||
| Q4 24 | $-16.7M | $-2.2M | ||
| Q3 24 | $-16.8M | $-1.8M | ||
| Q2 24 | $-1.6M | $-2.5M | ||
| Q1 24 | $-16.2M | $-3.2M |
自由现金流PMVPRKDA
| Q4 25 | $-17.2M | — | ||
| Q3 25 | $-19.8M | — | ||
| Q2 25 | $-18.3M | — | ||
| Q1 25 | $-18.3M | — | ||
| Q4 24 | $-16.7M | — | ||
| Q3 24 | $-16.8M | — | ||
| Q2 24 | $-1.6M | $-2.5M | ||
| Q1 24 | $-16.8M | $-3.2M |
自由现金流率PMVPRKDA
| Q4 25 | -1396.4% | — | ||
| Q3 25 | -1339.3% | — | ||
| Q2 25 | -1083.6% | — | ||
| Q1 25 | -944.2% | — | ||
| Q4 24 | -731.0% | — | ||
| Q3 24 | -644.0% | — | ||
| Q2 24 | -57.2% | -188.3% | ||
| Q1 24 | -568.4% | -326.5% |
资本支出强度PMVPRKDA
| Q4 25 | 1.2% | 0.0% | ||
| Q3 25 | 0.1% | 0.0% | ||
| Q2 25 | 0.7% | 0.0% | ||
| Q1 25 | 0.2% | 0.0% | ||
| Q4 24 | 2.4% | 0.0% | ||
| Q3 24 | 0.0% | 0.0% | ||
| Q2 24 | 0.1% | 0.2% | ||
| Q1 24 | 20.1% | 1.3% |
现金转化率PMVPRKDA
| Q4 25 | — | — | ||
| Q3 25 | — | -0.30× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -0.61× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -2.31× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
